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Abstract
Zika virus is a flavivirus transmitted via mosquito bite, blood transfusion, sexual intercourse or from mother-
to-child during gestation. Although neurologic complications of Zika virus infection are rare, Guillain-Barré 
syndrome (GBS) is the most common manifestation and typically develops soon after the initial systemic 
manifestations of Zika virus infection. This syndrome typically starts in the distal limbs with symmetric sensory 
abnormalities and progresses to involve weakness and decreased or absent deep tendon reflexes. Severe 
cases may also involve respiratory and cardiovascular impairment requiring care in an intensive care unit, 
and ventilator or circulatory support. A review of 166 published cases of GBS associated with Zika virus is 
notable for lower mortality than seen with sporadic GBS, but limited data regarding long-term outcome. When 
available, treatment with intravenous IgG (IVIg) or plasmapheresis, can reduce the severity and duration of 
symptoms.
Keywords: Zika Virus; Neurologic Manifestations; Central Nervous System Infection; Guillain-Barré Syndrome. 
Resumen
El virus zika es un flavivirus transmitido a través de la mordedura de mosquito, transfusión de sangre, la 
relación sexual o de madre a hijo durante la gestación. Aunque las complicaciones neurológicas de la 
infección por el virus zika son raras, el síndrome de Guillain-Barré (GBS) es la manifestación más común 
y normalmente se desarrolla poco después de las manifestaciones sistémicas iniciales de la infección por 
el virus. Este síndrome comienza en las extremidades distales con alteraciones sensoriales simétricas y 
progresa hasta involucrar la debilidad y la disminución o ausencia de reflejos tendinosos profundos. Los 
casos graves pueden implicar deterioro respiratorio y cardiovascular, requiriendo atención en una unidad de 
cuidados intensivos, así como ventilador o soporte circulatorio. Una revisión de 166 casos publicados de GBS 
asociados con el virus zika se caracteriza por una menor mortalidad que los observados con GBS esporádica, 
pero los datos son limitados con respecto a resultados a largo plazo. Cuando esté disponible, el tratamiento 
con IgG intravenoso (IVIg) o plasmaféresis puede reducir la gravedad y duración de los síntomas.
Palabras clave. Virus Zika; Manifestaciones Neurológicas; Infección del Sistema Nervioso Central; Síndrome 
de Guillain-Barré.
SIMPOSIO VIRUS ZIKA
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INTRODUCCIÓN
Zika virus is an arthropod-borne RNA virus 
in the flaviviridae family, a family that in-
cludes other neurotropic viruses such as 
dengue, yellow fever, Japanese encephali-
tis, West Nile and Saint Louis encephalitis 
viruses. Although Zika virus was first de-
scribed in Uganda in 1947, it was not iden-
tified as a cause of neurologic disorders 
until Guillain-Barré syndrome (GBS) was 
reported in French Polynesia in 2013 (1,2). 
Since then, Zika virus infection has also 
been associated with microcephaly, en-
cephalitis and myelopathy. Microcephaly 
in Brazil was initially reported in early 
2016 and will be discussed in a separate 
manuscript. Encephalitis or meningoen-
cephalitis associated with Zika virus infec-
tion has been reported in four patients, 
with Zika virus detected in cerebrospinal 
fluid (CSF) of three of the four patients 
and anti-Zika antibodies detected in CSF 
of the fourth patient (3-5). Acute myelitis 
has also been reported in one patient, 
also confirmed through detection of Zika 
virus in CSF (6). As GBS associated with Zika 
virus infection is currently the most com-
mon neurologic manifestation in adults, 
this review will focus on the clinical fea-
tures, diagnosis and management of GBS.
GUILLAIN-BARRÉ SYNDROME
Guillain-Barré syndrome (GBS) is a com-
mon cause of acute flaccid paralysis 
throughout the world. The syndrome 
is rare and most often follows a bacte-
rial or viral infection, or less frequently, 
vaccination. Symptoms typically include 
weakness and sensory abnormalities but 
may also include cranial nerve abnormali-
ties, such as ophthalmoplegia (the Fisher 
syndrome). Weakness starts in the distal 
limbs, then progresses proximally, and can 
progress to paralysis; is typically associat-
ed with decreased or absent deep tendon 
reflexes as well as sensory loss, paresthe-
sia or dysesthesia that starts in the periph-
eral limbs and ascends proximally.
Guillain-Barré syndrome associated 
with Zika virus infection
The onset of neurologic symptoms typi-
cally follows a prodromal illness that may 
include rash, fever, arthritis and conjunc-
tivitis. The median onset of neurologic 
symptoms of GBS following transient ill-
ness with Zika virus is 6-10 days, which 
is similar to the median interval of 9 
days reported between onset of neu-
rologic symptoms of GBS and diarrhea 
due to Camphylobacter jejuni infection 
(7-10). Given the lack of prior reports of 
GBS in Uganda, some experts have pos-
tulated that prior exposure to another 
arboviral infection, specifically dengue or 
chikungunya, is necessary for Zika to pro-
duce GBS through an immune-mediated 
mechanism. In one study, evidence of 
prior dengue infection was present in 32 
(86%) of 37 patients with GBS (9). In this 
same study, 20 (29.4%) of 68 patients 
with Zika virus-associated GBS had onset 
of neurologic symptoms during or imme-
diately following the viral prodrome, sug-
gesting a portion of the GBS symptoms 
could be due to direct effects of viral 
infection (9). Neuropathologic studies in 
human and non-human primate fetuses 
have detected Zika virus in brain tissue 
(11,12). Immunohistochemical assays have 
further localized Zika virus infection to 
neurons and glial cells (13). Neuropatho-
logic studies of patients with Zika-associ-
ated GBS have not been published.
The clinical symptoms associated with 
GBS due to Zika virus infection are similar 
to those due to other etiologies of GBS. 
Table 1 provides an overview and sum-
mary of specific symptoms, neurologic 
findings and frequency of respiratory 
and intensive care unit support required 
for patients with Zika-associated GBS. Al-
though there is no particular neurologic 
finding that would suggest Zika virus over 
an alternate etiology, clinical symptoms 
typically appear distally and symmetri-
cally, as opposed to West Nile virus infec-
tion, which typically produces an asym-
metric flaccid paralysis similar to polio (14).
Diagnosis
Diagnosis of GBS requires confirmation 
of a peripheral neuropathy by neuro-
physiologic testing (15). There are mul-
tiple potential types of peripheral nerve 
dysfunction associated with GBS (acute 
inflammatory demyelinating polyneu-
ropathy, AIDP; acute motor and sensory 
axonal neuropathy, AMSAN; acute mo-
tor neuropathy, AMAN; acute sensory 
neuronopathy, acute pandysautonomia 
and overlap syndrome) and criteria for 
electrodiagnosis vary with the subtype of 
GBS. Measurement of nerve conduction 
velocity and needle electromyography 
are used to characterize and confirm the 
presence of demyelinating polyradiculo-
neuropathy or axonal damage in affected 
limbs. Specific guidelines are available to 
help diagnose and differentiate between 
the various forms of GBS (15). The likeli-
hood of detecting abnormalities with 
neurophysiologic testing is maximal at 7 
or more days following onset of illness. 
Lumbar puncture in patients with GBS 
should demonstrate less than 50 white 
blood cells/µl in CSF and, when CSF is 
obtained at least two days after symp-
toms develop, often reveals a “cytoalbu-
minologic dissociation” – an elevation of 
CSF protein greater than 45 mg/dL (this 
level may vary by local laboratory). Lum-
bar puncture is also useful for excluding 
other infectious causes of acute flaccid 
paralysis. The Brighton criteria were de-
veloped to provide guidelines for diag-
nosing GBS with four levels of diagnostic 
certainty (Table 2) (16). These criteria in-
corporate clinical, electrodiagnostic and 
CSF findings and provide a useful tool for 
case ascertainment of GBS.
As is the case for many viral infections 
of the central nervous system (CNS), de-
tection of virus in CSF is transient and 
is often absent by the time neurologic 
symptoms develop. As GBS is often an 
immune-mediated response to the CNS 
initiated by a bacterial or viral infection, 
detection of Zika virus in CSF is not neces-
sary, but is more likely if neurologic symp-
toms start during the prodromal stage 
with systemic symptoms, such as rash 
and arthralgia. Current assays can direct-
ly detect Zika virus RNA or the immune 
response developed by the immune sys-
tem against the Zika virus (Table 3) (17). 
During the initial viremic period, real-
time reverse transcriptase polymerase 
chain reaction (rRT-PCR) can be used to 
detect virus in blood, CSF, saliva or urine 
up to a week after onset of symptoms 
(18). A positive rRT-PCR confirms the pres-
ence of Zika virus infection, but as vire-
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mia is transitory, a negative test does not 
exclude the diagnosis. Presence of Zika 
virus RNA in urine has been reported to 
start approximately two weeks after on-
set of viral symptoms and in one patient 
persisted for 48 days, suggesting that 
duration of detection of viral RNA by rRT-
PCR may vary across body fluids (9,19).
The detection of specific IgM antibod-
ies or a significant rise in the anti-Zika IgG 
titer in a pair of samples taken at least 
two weeks apart provides evidence of an 
acute infection. Anti-Zika virus IgM can 
be detected by enzyme-linked immuno-
sorbent assay (ELISA) in CSF or serum 
following the initial viremic phase until 
about 12 weeks after infection. Neutral-
izing antibodies to Zika virus develop 
following appearance of IgM antibod-
ies, are primarily IgG, and typically per-
sist for years. Unfortunately, Zika virus 
antibody assay results can be obscured 
due to cross-reactivity with other flavi-
viruses, which can prevent identification 
of the specific infecting virus, especially 
in a person previously infected with or 
vaccinated against a related flavivirus 
(20). The plaque reduction neutralization 
test (PRNT) allows discrimination of anti-
Zika virus antibodies from other potential 
cross-reacting antibodies due to other 
flavivirus infections. Although a PRNT ≥ 
4-fold titer is typically used to confirm 
an infection, the U.S. Centers for Disease 
Table 1. Clinical features of Guillain-Barré Syndrome associated with Zika virus infection. Compiled from references (1, 7-9, 24, 25). 
Publication
Clinical feature
Arias
(n=19)
Dirilikov
(n=34)
Oehler
(n=1)
Cao-Lorameau 
(n=42)º
Do Rosario 
(n=2)
Parra
(n=68)
Total 
(n=166)
Male gender 12 (63.2%) 14 (41%) - 31 (74%) 1 (50%) 38 (565) 96/165 (58%)
Median onset days 
(Range)
10 (2-20) 5 (0-17) 7 6 (4-10) 9 (8-10) 7 (3-10) -
Rash 17 (89%) 18 (56%) 1 (100%) 29/36 (81%) 2 (100%) 40 (59%) 107/160 (67%)
Fever 15 (79%) 12 (30%) 1 (100%) 18/31 (58%) 1 (50%) 47 (69%) 94/155 (61%)
Arthritis 14 (74%) - 1 (100%) 23/31 (74%) 2 (100%) 15 (22%) 55/121 (45%)
Conjunctivitis 7 (37%) - 1 (100%) 15/31 (48%) 0 (0%) 17 (25%) 40/121 (33%)
Diarrhea - 7/21 (34%) - - - -
Facial palsy 8 (42.1%) 20/32 (63%) 1 (100%) 33 (79%) 2 (100%) 34 (50%) 98/164 (60%)
Bilateral Bilateral 25 (60%) All Bilateral All Bilateral
Dysphagia 5 (26%) 19/32 (59%) - 19 (45%) 2 (100%) - 45/95 (47%)
Paresthesias 14 (73.7%)  Leg 24/32 (75%) 1 (100%) 35 (83%) 2 (100%) 52 (76%) 128/164 (78%)
Limb paresis Upper 13 (68.4%) Upper 24/32 (75%) 1 (100%) 33 (79%) 2 (100%) 66 (97%) 152/164 (93%)
Lower 19 (100%) Lower 31/32 (97%) Lower 17 (40%)
Areflexia 18 (95%) 31/32 (97%) 1 (100%) 20 (48%) 2 (100%) 64 (94%) 136/164 (83%)
Increased CSF protein 8 (42.1%) 25/25 (100%) 1 (100%) 39 (93%) 2 (100%) 45/55 (82%) 120/144 (83%)
Respiratory assistance 15 (79%) 12/32 (29%) - 12 (29%) - 21 (31%) 60/161 (37%)
Labile blood pressure 
Hypotension
15 (79%) - 1 (100%) - - 41 (31%) 57/88 (65%)
ICU stay 19 (100%) 21 (62%) 0 (0%) 16 (30%) 0 (0%) 40 (59%) 56/95 (59%)
Disability (3 months) - - * 24/57 ** - -
Death 0/19 (0%) 1/34 (3%) 0/1 (0%) 0/42 (0%) 0/2 (0%) 3/68 (4%) 4/166 (2.4%)
* Day 4: Walking without assistance.
** Day 28: House-Brackmann Grade 2, Day 47: House-Brackmann Grade 3.
Table 2.  Key diagnostic criteria and Brighton case definitions for Guillain-Barré syndrome.
Level of diagnostic certainty
Diagnostic criteria 1 2 3 4
Bilateral and flaccid weakness of limbs + + + + / -
Decreased or absent deep tendon reflexes in weak limbs + + + + / -
Monophasic course and time between onset-nadir 12 h to 28 days + + + + / -
CSF cell count <50 white blood cells/mL + + (a) - + / -
CSF protein concentration > 45 mg/dL + + / - (a) - + / -
Nerve conduction study consistent with one of the subtypes of GBS + + / - - + / -
No alternative diagnosis for weakness + + + +
+ present; - absent; + / - present or absent.
(a) If CSF results not available, nerve conduction study must be consistent with diagnosis of Guillain-Barré syndrome.
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Control and Prevention has suggested a 
more conservative approach using a titer 
of ≥ 10 against Zika virus and PRNT < 10 
against other flaviviruses to confirm in-
fection (17).
Similar to the Brighton Criteria de-
veloped to provide levels of diagnostic 
certainty for GBS, the World Health Or-
ganization has developed criteria to de-
termine level of certainty for diagnostic 
assays for Zika virus infection (21). These 
levels of diagnostic certainty have been 
further modified to include CSF testing 
by Parra and colleagues (9), with definite 
infection requiring detection of Zika vi-
rus RNA by rRT-PCR assay in blood, CSF 
or urine; probable infection requiring de-
tection of anti-Zika antibodies by ELISA in 
the CSF or serum, as well as exclusion of 
dengue virus serotypes; and suspected 
infection requiring two or more features 
of the PAHO case definition without labo-
ratory confirmation (Table 3). 
Treatment 
Treatment of GBS is often symptomatic, 
but as respiratory and cardiovascular 
systems can also be affected, experts 
recommend monitoring in an intensive 
care setting where respiratory and blood 
pressure support are available. In ad-
dition to symptomatic treatment, GBS 
can be treated with plasmapheresis or 
high dose intravenous immunoglobulins 
(IVIg). As plasmapheresis requires spe-
cialized equipment for plasma exchange, 
this procedure is often limited to special-
ized reference centers and to patients 
affected by respiratory compromise or 
hypotension. Although IVIg is easier to 
administer, cost of treatment is high, typ-
ically costing over $US10 000 for a five-
day course of 0.4 g/kg bodyweight. 
Although outcome of GBS is gener-
ally quite good, 5-15% of patients die 
and 20% remain disabled at one year (22). 
Factors associated with poor prognosis 
include requiring mechanical ventila-
tion, rapid onset of weakness and severe 
weakness at nadir of illness (23). Although 
long-term neurologic outcome follow-
ing Zika-associated GBS is not yet clear, 
reports suggest mortality from Zika-asso-
ciated GBS, when appropriate intensive 
care services and treatment are available, 
is less than 5%. Reports of long-term out-
come following Zika-associated GBS are 
few, but suggest the majority of patients 
recover the ability to walk without assis-
tance (Table 1). 
CONCLUSIONS
The neurologic complications of Zika 
virus infection in adults include Guillain-
Barré syndrome (GBS), meningitis, 
encephalitis and myelitis. The most 
common of these complications is GBS. 
Table 3. Key clinical and laboratory diagnostic criteria for Zika virus infection with and without Guillain-Barré Syndrome.
Zika virus disease Zika associated GBS
Clinical AND Laboratory Clinical AND Laboratory
Suspected*
Patient with rash with two 
or more of the following 
signs or symptoms:
1) Fever <38.5° C
2) Conjunctivitis (non-
purulent/ hyperemic)
3) Arthralgia
4) Myalgia
5) Peri-articular edema
No laboratory confirmation
Bilateral and flaccid 
weakness of the limbs
AND
Decreased or absent deep 
tendon reflexes in weak 
limbs
AND
Monophasic illness pattern, 
with interval between onset 
and nadir of weakness 
between 12 hours and 
28 days, and subsequent 
clinical plateau 
AND 
Absence of identified 
alternative diagnosis for 
weakness**
No laboratory confirmation
Probable
Zika IgM antibodies without evidence of 
other flavivirus infection
Detection of anti-Zika antibodies by 
enzyme-linked immunosorbent assay 
(ELISA) in CSF, serum, or urine and 
exclusion of the four dengue virus 
serotypes
Confirmed
RNA or Zika virus antigen detected in 
serum, urine, saliva, tissue or whole blood; 
OR
Positive Zika IgM antibodies AND Plaque 
reduction neutralization (PRNT90) for Zika 
virus titers = 20 and ≥ four times greater 
than titers for other flaviviruses; AND 
exclusion of other flavivirus; OR
detection of Zika viral genome in 
autopsy specimen (fresh or paraffin 
tissue) by molecular techniques or 
immunohistochemistry
Detection of Zika virus RNA by real-
time reverse-transcriptase polymerase 
chain reaction (RT-PCR) assay in blood, 
CSF or urine
*Adapted from PAHO Zika: Case Definition (7).  Suspected case requires potential exposure through 1) Zika virus disease in geographic areas with autochthonous transmission 
and vectors are present; OR 2) travel to or residing in, a geographic area with known vector presence or Zika virus transmission within 2 weeks prior to onset of symptoms; OR 3) 
un-protected sex, in the 2 weeks prior to onset of symptoms, with a person who traveled, in the previous 8 weeks, to a geographic area with (a) known local transmission of the Zika 
virus or (b) an area with known vector presence.  
** See Table 1 for levels of diagnostic certainty.
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The clinical presentation and course of 
illness of GBS due to Zika virus infection 
appears to be very similar to GBS caused 
by other etiologies. Healthcare providers 
in areas where Zika is endemic, or who 
evaluate patients who have recently 
traveled through an endemic area or 
had sex with a person who may have had 
Zika infection, should consider Zika virus 
as a possible etiology of GBS. Treatment 
frequently requires an intensive care 
unit to provide support for respiratory 
and cardiovascular decompensation. 
In addition, IVIg and plasmapheresis, 
where available, can reduce duration and 
severity of symptoms.
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